University of California, San Francisco
San Francisco, California, 94143, United States
Location status: Recruiting
Location contact
Javier Villanueva-Meyer, MD
PRINCIPAL_INVESTIGATOR
Louise Magat
CONTACT
Thomas Hope, MD
SUB_INVESTIGATOR
CONTACT
NCT Number: NCT06474533
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Interested in participating?
Request Info4 year and older
All sexes
Observational
San Francisco, California, 94143, United States
Location status: Recruiting
Javier Villanueva-Meyer, MD
PRINCIPAL_INVESTIGATOR
Louise Magat
CONTACT
Thomas Hope, MD
SUB_INVESTIGATOR
CONTACT
PRIMARY OBJECTIVES:
SECONDARY OBJECTIVES:
EXPLORATORY OBJECTIVES:
OUTLINE:
Participants will receive a single PET scan lasting for about 40 minutes in an outpatient setting after an injection with FET. Adult participants may undergo up to two repeat FET PET scans. Adverse events will be recorded.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.
Exclusion criteria
Given intravenously (IV)
Other names: Fluoroethyltyrosine (FET), FET, O-(2-[18F]fluoroethyl)-L-tyrosine (FET)
Undergo Imaging Procedure
Other names: PET scan, PET
Time frame: Up to 3 years
The maximum TBR (TBRmax) will be calculated by dividing the SUVmean of the 1.6 centimeter (cm) diameter circular region of interest (ROI) by the mean standardized uptake value (SUVmean) of background normal tissue.
Time frame: Up to 3 years
The percentage of radiological read responses that accurately predict the presence of recurrent tumor in patients previously treated with surgery and/or radiation for population 1, broken down by metastatic disease, high-grade gliomas and low-grade gliomas will be reported
Time frame: Up to 3 years
The percentage of radiological reads with a binary characterization of scan study as positive for recurrence disease in population 1, and positive for high-grade glial neoplasm in population 2 will be reported.
Contact information is provided by the study sponsor or research team.
Thomas Hope
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04278118
Brain Diseases, Brain Neoplasms
Atlanta, Georgia, United States
View Trial DetailsNCT04044937
Astrocytoma, Brain Diseases
San Francisco, California, United States
View Trial DetailsNCT03076255
Brain Diseases, Brain Neoplasms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05145049
Brain Diseases, Brain Neoplasms
Ankara, Turkey (Türkiye)
View Trial Details